Co-opting signalling molecules enables logic-gated control of CAR T cells-Reference-Cited by-同舟云学术

Co-opting signalling molecules enables logic-gated control of CAR T cells

Published:2023-03-08 Issue:7952 Volume:615 Page:507-516
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Tousley Aidan M.^ORCID,Rotiroti Maria Caterina,Labanieh Louai,Rysavy Lea Wenting,Kim Won-Ju^ORCID,Lareau Caleb^ORCID,Sotillo Elena^ORCID,Weber Evan W.,Rietberg Skyler P.,Dalton Guillermo Nicolas,Yin Yajie^ORCID,Klysz Dorota,Xu Peng,de la Serna Eva L.,Dunn Alexander R.^ORCID,Satpathy Ansuman T.^ORCID,Mackall Crystal L.^ORCID,Majzner Robbie G.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-023-05778-2.pdf

Reference64 articles.

1. Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341–1355 (2019).

2. June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).

3. Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71–75 (2013).

4. Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic Notch receptors. Cell 167, 419–432 (2016).

5. Fedorov, V. D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl Med. 5, 215ra172 (2013).

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR-T in cancer therapeutics and updates;Journal of the National Cancer Center;2024-09

2. Self-delivery nanodrug to manipulate tumor microenvironment for boosting photodynamic cancer immunotherapy;Biomedicine & Pharmacotherapy;2024-09

3. Exploiting protein domain modularity to enable synthetic control of engineered cells;Current Opinion in Biomedical Engineering;2024-09

4. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

5. Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy;Advanced Materials;2024-08-20